Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pharmaxis Ltd ( (AU:SNT) ) just unveiled an update.
Syntara Limited has announced key strategic appointments to aid in the clinical and commercial development of its lead drug candidate, amsulostat, for myelofibrosis. The new advisors and clinical board members bring extensive experience in haematology and oncology, which is expected to significantly bolster Syntara’s efforts in advancing amsulostat through clinical trials and towards potential market approval. This move is seen as a strategic step to enhance Syntara’s positioning in the drug development industry, particularly in the field of blood cancers.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Syntara Limited is a clinical-stage drug development company specializing in targeting extracellular matrix dysfunction. With expertise in amine oxidase chemistry, Syntara develops novel medicines for blood cancers and conditions related to inflammation and fibrosis. Their lead candidate, amsulostat, is aimed at treating myelofibrosis, a bone marrow cancer. The company is also advancing other drug candidates for various fibrotic and inflammatory diseases and has previously developed respiratory products.
Average Trading Volume: 4,424,039
Technical Sentiment Signal: Sell
Current Market Cap: A$40.81M
For detailed information about SNT stock, go to TipRanks’ Stock Analysis page.